STARPHARMA

STARPHARMA

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Starpharma_logo

Industry:
Company

Founded:
1996

Address:
4-6 Southampton Crescent, Abbotsford, VIC, Australia Zipcode 3067

Country:
Australia

Phone:
61 3 8532 2700

Market Cap:
777.64M
Total Revenue:
6.56M
Total Assets:
39.08M
Total Cash:
30.05M

Chairman: Rob Thomas


Key Executives
Name Title Pay Year Born
Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD CEO, MD & Exec. Director 579,153$ 1963(57 years old)
Mr. Nigel J. Baade B.Com, Grad. Dip., CPA CFO & Company Sec. 283,078$ N/A



Financial & Stock
Exchange ASX. Currency in AUD. Market state PRE
According to Starpharma's financial reports the company's revenue in 2020 were 6.56M an increase( +200%) over the years 2019 revenue that were of 2.72M. In 2020 the company's total earnings were -14.68M while total earnings in 2019 were -14.25M(0%).
Company's stock symbol is SPL.AX. Lastest price : 1.9150. Total volume :569.05k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.starpharma.com

  • Host name: 111.223.234.218
  • IP address: 111.223.234.218
  • Location: Robina Australia
  • Latitude: -28.0697
  • Longitude: 153.3907
  • Timezone: Australia/Brisbane
  • Postal: 4226

Loading ...
Loading ...


More informations about "Starpharma" on Search Engine

Home - Starpharma

Starpharma.com Starpharma is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications SPL7013 active against other pandemic coronaviruses Interim Report and Half-Year Financial Results VIRALEZE™ antiviral nasal spray registered in Europe

Home - Starpharma

Starpharma.com Starpharma signs new DEP® partnership with Chase Sun. Jul 2020. Jul 30th, 2020. DEP® …

Home - Starpharma

Starpharma.com DEP® HER2-lutetium outperforms in human breast cancer model Mar 16th, 2021 …

Home - Starpharma

Starpharma.com About Starpharma. Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a …

Home - Starpharma

Starpharma.com VivaGel® VivaGel ® is an innovative technology being applied to a range of …

Home - Starpharma

Starpharma.com Starpharma’s dendrimers can be used to enhance the properties of other drugs. The …

Home - Starpharma

Starpharma.com Annual Reports: Annual Report 2019 (pdf file, 4.5MB): Annual Report 2018 ( pdf file, …

Home - Starpharma

Starpharma.com Dec 12, 2018. US patent granted for SPL7013 eye drops for conjunctivitis. Melbourne, …

About Us - Starpharma

Starpharma.com Starpharma has developed VIRALEZE™, an antiviral nasal spray for COVID-19, which is complementary to vaccines and other preventative measures such as distancing and PPE. VIRALEZE™ is registered for sale in the UK/Europe and available in the UK through LloydsPharmacy.

STARPHARMA HOLDINGS LIMITED (SPHRY) Stock Price, News

Finance.yahoo.com Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ …

SPHRY Stock Price | Starpharma Holdings Ltd. ADR Stock

Marketwatch.com Mar 29, 2021 · Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. …

Starpharma creates slow release soluble DEP remdesivir

Finance.yahoo.com Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has applied its novel DEP ® drug delivery technology to create a long‑acting, water soluble version of remdesivir. Remdesivir is an ...

Why the Starpharma (ASX:SPL) share price is tumbling lower

Fool.com.au Mar 30, 2021 · This morning Starpharma announced that its Viraleze antiviral nasal spray has now been launched in the UK by LloydsPharmacy. Viraleze is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013), which is virucidal and irreversibly inactivates >99.9% of the virus that causes COVID-19 within one minute.

Starpharma - producent wyrobów medycznych i suplementów diety

Starpharma.pl Administratorem Twoich danych osobowych jest Starpharma sp. z o.o. z siedzibą w Warszawie, ul. Stawki 2, 23 piętro, 00-193 Warszawa, email: [email protected], nr tel.: (0-22) 403 63 02. Pozyskane dane będą przetwarzane przez okres 5 lat od dnia pozyskania danych oraz zgodnie z obowiązującymi przepisami prawa.

Remdesivir Gets The Starpharma DEP Treatment (OTCMKTS)

Seekingalpha.com Starpharma has recently expanded its DEP-couplings to include linking the core DEP particles with radioisotopes. Radioisotopes are used for both therapy and diagnosis of disease, especially cancer.

Why the Starpharma (ASX:SPL) share price is tumbling lower

Msn.com The Starpharma Holdings Limited share price has come under pressure on Tuesday despite the release of a positive announcement. In afternoon trade, the dendrimer products developer’s shares are ...

Starpharma share price bolts 14% on COVID-19 nasal spray

Msn.com Starpharma is an Australian based biopharmaceutical company that develops products for pharmaceutical, life science and other applications. The company’s underlying …

STARPHARMA HOLDINGS Share Price - SPL Share Price

Stockopedia.com Starpharma Holdings Limited is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The Company utilizes dendrimers, which is a type of synthetic nanoscale polymer that is regular in size and structure and suited to pharmaceutical and medical uses.

Starpharma Holdings Limited (ASX:SPL) Share Price News

Fool.com.au Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialisation of dendrimer products for pharmaceutical, life-science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis, and as a condom coating.

Starpharma : VIRALEZE™ to be launched with LloydsPharmacy

Marketscreener.com Starpharma's sales and distribution agreement with LloydsPharmacy/McKesson incorporates a reciprocal exclusivity arrangement for VIRALEZE™ with significant investment in marketing by Lloyds, both online and instore. LloydsPharmacy has around 1,400 pharmacies across the UK.

SPL:ASE Stock Quote - Starpharma Holdings Ltd - Bloomberg

Bloomberg.com Starpharma Holdings Limited is biotechnology company involved in the research, development, and commercialization of dendrimer-based for pharmaceutical, life sciences, and other applications.

Starpharma to launch anti-COVID nasal spray with major UK

Businessnewsaustralia.com Mar 25, 2021 · Pharmaceuticals manufacturer Starpharma (ASX: SPL) will commence the rollout of its COVID-killing nasal spray in the UK after signing a deal with a major pharmacy chain. The groups antiviral nasal spray called VIRALEZE will be stocked by LloydsPharmacy, a pharmacy chain in the UK with around 1,400 stores across the cou

Condom gel compound proves effective against COVID-19

Afr.com Apr 16, 2020 · Starpharma has filed a patent for the usage of its antiviral compound against COVID-19. The company's condom and vaginal lubricants are already on sale in …

Starpharma: At Last It Is Happening (OTCMKTS:SPHRY)

Seekingalpha.com Starpharma is already in discussions concerning licensing the VivaGel BV applications in partnership with a global healthcare investment bank. VivaGel BV is already approved for treatment of BV in...

Marius Calleja – General Manager, Starpharma, Malta

Pharmaboardroom.com Starpharma has been operational in Malta since 2001, the second pharmaceutical company established in the country. In May 2017, the company was acquired from Valpharma, the Italian founder. The new acquisition was composed of a Maltese company, Healthy …

Starpharma eyes long-lasting, subcutaneous Veklury doses

Fiercepharma.com Sep 04, 2020 · Starpharma has developed a long-acting, water-soluble version of Veklury—still the only antiviral approved to tackle the novel coronavirus—using its drug delivery platform DEP.. Centered on ...

Starpharma's anti-COVID nasal spray approved in Europe and

Businessnewsaustralia.com Feb 23, 2021 · Australian pharmaceutical company Starpharma's (ASX: SPL) anti-COVID nasal spray VIRALEZE has been approved for sale in Europe and the UK today, and is now on track to launch next month. Shares in SPL have spiked on the announcement, up more than 9 per cent in early trade.

Starpharma Holdings Limited (ASX:SPL) - Shares, Dividends

Intelligentinvestor.com.au Apr 01, 2021 · Starpharma Holdings Limited (SPL) is a biotechnology company that engages in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma Holdings (ASX:SPL) - Share price, News

Simplywall.st Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.

SPHRY:OTC US Stock Quote - Starpharma Holdings Ltd

Bloomberg.com Starpharma Holdings Limited is biotechnology company involved in the research, development, and commercialization of dendrimer-based for pharmaceutical, life sciences, and other applications.

Starpharma (ASX:SPL) shares rise on breast cancer

Themarketherald.com.au Mar 16, 2021 · Starpharma (SPL) shares are on the rise this morning after its second radiopharmaceutical candidate, DEP HER2-lutetium, achieves anti-cancer activity in breast cancer. Importantly, the drug outperformed Herceptin, a treatment for a type of breast cancer called HER2 positive, or human epidermal growth factor receptor 2.

Starpharma Holdings Ltd, SPL:ASX profile - FT.com

Markets.ft.com Starpharma Holdings Limited is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The Company utilizes dendrimers, which is a type of synthetic nanoscale polymer that is regular in size and structure and suited to pharmaceutical and medical uses.

Pudroderm | Starpharma

Starpharma.pl Administratorem Twoich danych osobowych jest Starpharma sp. z o.o. z siedzibą w Warszawie, ul. Stawki 2, 23 piętro, 00-193 Warszawa, email: [email protected], nr tel.: (0-22) 403 63 02. Pozyskane dane będą przetwarzane przez okres 5 lat od dnia pozyskania danych oraz zgodnie z obowiązującymi przepisami prawa.

Starpharma SPL7013 Nasal Spray for COVID-19 – Development

Businesswire.com Aug 25, 2020 · Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to …

Astodrimer - Starpharma - AdisInsight

Adisinsight.springer.com Starpharma, in Decemebr 2018 signed a licence agreement with ITF Pharma for the sales and marketing rights to VivaGel ® BV in the United States for a term of 10 years or patent expiry (at least 2030 with potential extensions out to 2033) including customary provisions to extend the agreement.

Docetaxel - Starpharma - AdisInsight

Adisinsight.springer.com A dendrimer anion formulation of docetaxel is being developed by Starpharma using its DEP technology, for the intravenous treatment of solid tumours, including

Starpharma (OTCMKTS:SPHRY) vs. PPD (NASDAQ:PPD) Head to

Themarketsdaily.com 21 hours ago · Starpharma (OTCMKTS:SPHRY) and PPD are both medical companies, but which is the superior business?We will contrast the two businesses based on the strength of …

Starpharma | LinkedIn

Linkedin.com Starpharma is a global biopharmaceutical company and a world leader in the development of dendrimers.

Starpharma - Crunchbase Company Profile & Funding

Crunchbase.com Oct 04, 2006 · Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications. Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and.

Starpharma : Interim Report and Half-Year Financial

Marketscreener.com Starpharma Interim Report and Half-Year Financial Results. Melbourne, Australia; 25 February 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its interim report and financial results for the half-year ended 31 December 2020.. Key Financials • Cash balance at 31 December 2020 $70.3M (June 2020 $30.1M) • $47.0M net proceeds from equity placement and share purchase plan

Aussie biotech Starpharma signs deal to sell COVID nose

Smh.com.au Mar 25, 2021 · Starpharma started work on Viraleze around a year ago, convinced that SPL7013, the active antiviral compound that it already uses in registered antiviral condoms and …

Is Starpharma Holdings Stock risky? (AU:SPL) - Macroaxis

Macroaxis.com Starpharma Holdings Stock volatility depicts how high the prices fluctuate around the mean (or its average) price. In other words, it is a statistical measure of the distribution of Starpharma daily returns, and it is calculated using variance and standard deviation.

SPL News, Analysis, Announcements & Results | Starpharma

Afr.com Apr 07, 2021 · Starpharma’s VivaGel condom is a world-first product and the only condom of its type that provides barrier protection and incorporates a proprietary anti-viral compound Oct 27, 2014 Trevor Hoey

Starpharma | VentureRadar

Ventureradar.com " Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications. Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure ...

Here's Why We're Not At All Concerned With Starpharma

Simplywall.st Starpharma Holdings seems to be in a fairly good position, in terms of cash burn, but we still think it's worthwhile considering how easily it could raise more money if it wanted to. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in …

SPL - Starpharma Holdings Limited - Strawman: ASX share

Strawman.com Starpharma is rapidly advancing development, regulatory, manufacturing and commercialisation activities and leveraging its extensive technical data set and approved status of SPL7013 to expedite approval with product now expected to be ready for market 1H CY2021

Starpharma: Commencement of Phase 1 Trial for AZD0466

Businesswire.com Dec 29, 2019 · About Starpharma Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in …

Starpharma - Overview, News & Competitors | ZoomInfo.com

Zoominfo.com Starpharma signs DEP® ADC Research Agreement with MSD MELBOURNE, Australia, Feb. 11, 2021 /PRNewswire/ -- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA.

23. Starpharma - AusBiotech Ltd

Ausbiotech.org Starpharma . Starpharma is one of Australia’s most established biotechnology companies and has come a long way since its scientific genesis at the CSIRO. The company’s dendrimers, which are man-made, nanoscale polymers have been coated on Ansell condoms, combined with blockbuster chemotherapy drugs to improve efficacy and reduce side ...

Starpharma – drug delivery deal with Astra Zeneca | Monash

Monash.edu Starpharma – drug delivery deal with Astra Zeneca (Left to right) Professor Ben Boyd, Chris Porter, and Dr Lisa Kaminskas A long standing collaboration between MIPS scientists and the Melbourne-based biotechnology company Starpharma reached a significant commercialisation milestone when Starpharma signed a major licencing deal with the global ...

Starpharma to sell COVID-fighting nose spray in UK

Globalpharmatimes.com Mar 25, 2021 · Australian biotech company, Starpharma, has announced a deal with LloydsPharmacy to sell its COVID-fighting antiviral nasal spray, Viraleze, in the UK. The announcement follows Viraleze’s successful registration for sale in Europe on 23 February, and makes Starpharma the first ASX-listed biotech to bring a COVID-19 preventative product to a global retail market. The antiviral […]

Starpharma Holdings Revenue 2011-2020 | SPHRY | MacroTrends

Macrotrends.net Starpharma Holdings revenue from 2011 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and …

SPHRY Stock | STARPHARMA Stock Price Today | Markets Insider

Markets.businessinsider.com Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma: Commencement of Phase 1 Trial for AZD0466

Biospace.com Dec 29, 2019 · About Starpharma Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications. 1 3rd AstraZeneca-MedImmune-CRUK Cambridge Centre Symposium 2017 presentation

SPHRY | Starpharma Holdings Ltd. ADR Company Profile

Wsj.com Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. Its programs include: VivaGel portfolio, Drug ...